Company profile
West Pharmaceutical Services, Inc.
NYSE: WST · Healthcare · Medical - Instruments & Supplies
#86 of 1,422 Healthcare companies by revenue51st-percentile growth
EA Score
86AFH 89DQ 93GM 59SS 97
v0.1 · 65/100 weight · provisional
↑ filing timeliness, listing tenure · ↓ 3-yr revenue growth, revenue growth (YoY)
Methodology →Revenue TTM
$3.2B
Rev growth YoY (TTM)
+11.2%
Net income (FY)
$493.7M
Employees
10,800
as of 2026-08-05
Market cap
$24.5B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.1B$3.1B2025
Net income$493.7M$493.7M2025
Operating income$584.9M$584.9M2025
Total assets$4.3B$4.3B2025
Liabilities$1.1B$1.1B2025
Equity$3.2B$3.2B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Proprietary Products81%
Contract Manufactured Products19%
By geography
UNITED STATES43%
Other Europe Countries15%
GERMANY12%
Other Countries11%
IRELAND11%
FRANCE7%
The read
What is West Pharmaceutical Services, Inc.’s revenue?
West Pharmaceutical Services, Inc. booked $3.1B in FY2025 revenue, growing 6.3% year over year — about the middle of the pack among Healthcare companies we track, at a 16.1% net margin.
Peers · Healthcare
Astrana Health, Inc.75B+Waters Corporation82B+MiniMed Group, Inc. Common Stock73BAmneal Pharmaceuticals, Inc.75B+Globus Medical, Inc.86ANeurocrine Biosciences, Inc.88ANeighbors
Chester →Key facts
CEOEric Green
SectorHealthcare
IndustryMedical - Instruments & Supplies
HeadquartersExton, PA
ExchangeNYSE: WST
Employees10,800
IPO date1980-03-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.